February 2, 2011
BILLINGS, Mont.All American Pharmaceutical received a warning letter from FDA in mid-January, following up on a GMP (good manufacturing practice) inspection and related 483 observation form from August 2010. All American filed a response with FDA on Aug. 13, 2010, to the alleged GMP violations; however, FDA considered the response to be inadequate in several cases.
Specifically, FDA continues to be concerned about appropriate documentation related to master manufacturing records; issuance and use of labels related to batch production records; and possible deficiencies in segregating and identifying containers of product during manufacturing to avoid contamination. As All American did respond that its records have been updated, FDA said it intends to verify the adequacy of master manufacturing records and BPRs during its next inspection.
You May Also Like
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023
Radicle Insights—Covid Eris and dietary supplements: separating fact from fictionSep 21, 2023
More bioavailable hyaluronic acid complex for today’s beauty-from-within consumer – snapshotSep 18, 2023